Recursion Pharmaceuticals, INC 10-Q quarterly reports

Recursion Pharmaceuticals, Inc. reported a significant decrease in total revenue for the second quarter of 2026, alongside continued substantial operating losses, while highlighting progress in key collaborations and internal pipeline development.

Recursion Pharmaceuticals reports a decrease in revenue and operating costs for Q1 2026, with a net loss of $117.5 million, while advancing its drug discovery platform and pipeline.

Recursion Pharmaceuticals reported a significant increase in net loss for Q3 2025, driven by higher R&D expenses and strategic acquisitions, while advancing its AI-driven drug discovery pipeline.

Recursion Pharmaceuticals reported a significant increase in net loss for Q2 2025, driven by higher R&D expenses and the integration of recent acquisitions, while advancing its AI-driven drug pipeline.

Recursion Pharmaceuticals announces its Q1 2025 financial results, showcasing advancements in its pipeline and ongoing collaborations.

Recursion Pharmaceuticals announced its Q3 2024 financial results, showcasing increased revenue and advancements in its clinical programs and strategic partnerships.

Recursion Pharmaceuticals announced its second quarter 2024 financial results, alongside a strategic combination with Exscientia, aiming to create a leading TechBio company.

Recursion Pharmaceuticals' first quarter 2024 results show increased R&D spending as the company advances its pipeline and platform, while also reporting a net loss of $91.4 million.